TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01077375

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Placebo tablets, oral administration, twice daily for 10 weeks during randomized, double-blind treatment period. Duloxetine capsules, oral administration, 30 mg/day for 1 week after randomization to effect a duloxetine down-taper.~* Placebo tablets, twice daily for 1 week during double-blind down-taper treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milnacipran
Description: * Milnacipran tablets, 100 to 200 mg/day, oral administration, twice daily in divided doses for 10 weeks during randomized, double-blind treatment period. Placebo capsules, 1 capsule/day administered for 1 week after randomization to maintain double-blind duloxetine down-taper.~* Milnacipran tablets, 100 to 0 mg/day, oral administration, twice daily in divided doses for 1 week during double-blind down-taper treatment period.
Study: NCT01847807

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low dose Astragalus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: high dose astagalus
Study: NCT00162955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: Patients allocated into ARB administration group take Valsartan (80mg/day) from the day of the start of 1st CHOP until the completion of all the evaluations.
Study: NCT02539615

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ForeCYTE Breast Aspirator
Study: NCT04421547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5mg
Description: This study will investigate the role of Letrozole in patients affected by heavily pretreated platinum resistant ovarian cancer, compared to standard treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard single agent chemotherapy
Description: Either Paclitaxel 80 mg/m2 as a 1-h infusion, on days 1,8,15,22 every 28 days or Pegylated Liposomal Doxorubicin (PLD) 40 mg/m2 given every 4 weeks or Topotecan 4mg/m2 IV on days 1,8,15 every 4 weeks or Gemcitabine 1000 mg/m2 IV over 30 min on days 1,8,15 every 28 days.
Study: NCT03422653

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV medication delivered three times/week
Study: NCT03809624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INBRX-105 - PDL1x41BB antibody
Description: The active ingredient of INBRX-105 is a recombinant, humanized, bispecific IgG antibody that targets the human programmed death-ligand 1 (PD-L1) receptor and the human 4-1BB receptor.
Study: NCT02214615

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbamazepine
Description: Day 1: Take 200 mg twice a day. Day 2: Take 200 mg twice a day. Day 3: Take 200 mg twice a day. Day 4: Take 200 mg twice a day. Day 5: Take 400 mg twice a day. Day 6: Take 400 mg twice a day. Day 7: Take 400 mg twice a day. Day 8: Take 400 mg twice a day. Day 9: Take 600 mg twice a day. Day 10: Take 600 mg twice a day. Day 11: Take 600 mg twice a day. Day 12: Take 600 mg twice a day. Day 13: Take 800 mg capsules twice a day. Day 14: Take 800 mg twice a day. Day 15: 800 mg twice a day. Day 16: Take 800 mg twice a day.~Taper Down (After Visit 4 and 7) If maximal dose of 800 mg/day has been achieved, tapering down will take 9 days Taper down for 600 mg/day will take 6 days, and for 400 mg/day will take 3 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01538888

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: WHOLE BODY VIBRATION
Description: 03 MONTHS, TWICE PER WEEK
Study: NCT01061021

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In The Mix
Description: Five small group + 2 individual counseling intervention designed to addresses HIV transmission risk behavior and HIV treatment adherence in men and women living with HIV/AIDS.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information Support Group
Description: Five small group + 2 individual counseling session intervention that serves as an attention control group. Content included stress reduction, nutrition, and exercise for health improvement.
Study: NCT03283137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TGR-1202
Description: TGR-1202 will be given at a dose of 600mg (dose level 1) or 800mg (dose level 2). If the dose of 600mg is tolerated in the first cohort, then the dose will be increased to 800mg which is the only and final dose escalation. If the dose of 600mg is not tolerated, then the dose will be decreased to 400mg daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be given at 200 mg every 3 weeks. The dose will not be adjusted throughout the course of the study.
Study: NCT00891800

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: SIR-Sphere contains radiation of Y-90.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIR-Sphere
Description: Brachytherapy Radiation seeds
Study: NCT02892253

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near Infrared Camera (NIR)
Description: Surgical field is examined with NIR, during a few minutes (\<5') with room lights switched off, to avoid parasite lights, then open thyroidectomy is resumed conventionally. Real-time images, evocative of autofluorescent parathyroids, are checked visually. NIR consists of a 750 nm class 1 laser excitation, with a power \<20mW/cm2 (5 times less than the limit of 100mw/cm2, fixed by the international standard IEC 60601-2-41). It is provided by the Fluobeam® camera, which is inserted into a sterile cover and hold at a 15-20 cm distance from the patient. The system has an FDA 510(k) authorization for clinical use in parathyroid surgery and a European Community certification (Class 2A device).
Study: NCT02196766

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bioclean First Care EX / comfilcon A
Description: Subjects dispensed Bioclean First Care EX / comfilcon A combination then crossed over to the alternate combination.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bioclean First Care EX / comfilcon A
Description: Subjects dispensed Bioclean First Care EX / comfilcon A combination then crossed over to the alternate combination.
Study: NCT03809624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INBRX-105 - PDL1x41BB antibody
Description: The active ingredient of INBRX-105 is a recombinant, humanized, bispecific IgG antibody that targets the human programmed death-ligand 1 (PD-L1) receptor and the human 4-1BB receptor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INBRX-105 - PDL1x41BB antibody
Description: The active ingredient of INBRX-105 is a recombinant, humanized, bispecific IgG antibody that targets the human programmed death-ligand 1 (PD-L1) receptor and the human 4-1BB receptor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INBRX-105 - PDL1x41BB antibody
Description: The active ingredient of INBRX-105 is a recombinant, humanized, bispecific IgG antibody that targets the human programmed death-ligand 1 (PD-L1) receptor and the human 4-1BB receptor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INBRX-105 - PDL1x41BB antibody
Description: The active ingredient of INBRX-105 is a recombinant, humanized, bispecific IgG antibody that targets the human programmed death-ligand 1 (PD-L1) receptor and the human 4-1BB receptor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INBRX-105 - PDL1x41BB antibody
Description: The active ingredient of INBRX-105 is a recombinant, humanized, bispecific IgG antibody that targets the human programmed death-ligand 1 (PD-L1) receptor and the human 4-1BB receptor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INBRX-105 - PDL1x41BB antibody
Description: The active ingredient of INBRX-105 is a recombinant, humanized, bispecific IgG antibody that targets the human programmed death-ligand 1 (PD-L1) receptor and the human 4-1BB receptor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg by intravenous (IV) infusion, given on Day 1 of each 21-day cycle.
Study: NCT03277196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVA
Description: Granules for oral administration.
Study: NCT02196766

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aosept Clearcare / comfilcon A
Description: Subjects dispensed Aosept Clearcare / comfilcon A combination then crossed over to the alternate combination.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aosept Clearcare / comfilcon A
Description: Subjects dispensed Aosept Clearcare / comfilcon A combination then crossed over to the alternate combination.
Study: NCT02481830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amrubicin
Study: NCT03144505

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MCT combined with RT Group

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIIT combined with RT Group
Study: NCT01853657

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virological monitoring
Study: NCT03215693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X-396 capsule
Description: 225mg once daily
Study: NCT01433497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masitinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masitinib

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04188197

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUUL
Description: Subjects will be instructed to use the JUUL as often as they like during the 12-week product use period. They will also be instructed to use JUUL immediately before each cigarette to relieve their craving as much as possible before smoking their usual brand. The JUUL will also be the first product that they are instructed to use each morning. Smokers will be told to try to completely substitute JUUL for cigarettes by the end of the first week of use.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JUUL
Description: Subjects will be instructed to use the JUUL as often as they like during the 12-week product use period. They will also be instructed to use JUUL immediately before each cigarette to relieve their craving as much as possible before smoking their usual brand. The JUUL will also be the first product that they are instructed to use each morning. Smokers will be told to try to completely substitute JUUL for cigarettes by the end of the first week of use.
Study: NCT04664556

Intervention type: OTHER
Intervention: observational study
Description: observational study
Study: NCT01350557

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive care
Description: Comprehensive care consisted of subacute care plus health-maintenance interventions to manage depressive symptoms, manage malnutrition, and prevent falls.

Intervention type: OTHER
Group type: OTHER
Intervention: Subacute care
Description: Subacute care included geriatric consultation, continuous rehabilitation, and discharge planning.
Study: NCT00794456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Passiflora ; Crataegus and Salix
Description: 1 tablet PO twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valeriana
Description: 1 tablet PO twice a day
Study: NCT00770822

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIFU (Sonablate® 500)
Description: High Intensity Focused Ultrasound

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Brachytherapy
Description: Standard of care
Study: NCT02543632

Intervention type: DEVICE
Intervention: Parachute Implant System
Description: The CardioKinetix Parachute Implant partitions an enlarged ventricle into dynamic and static chambers. The static chamber is a portion of the left ventricular volume that is taken out of circulation. Stresses placed on the partitioned myocardium and the forces transmitted to the apical segment are decreased both in diastole and systole, eliminating the forces responsible for left ventricular dilation. In addition to this regional unloading, the reduction in size of the dynamic chamber results in a decrease of the myocardial stress in the normal myocardium via Laplace Law, providing a global unloading of the ventricle.
Study: NCT01356693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bromelin
Description: Ananas comosus extract (3,3g) on vehicle: methylparaben, propylparaben, honey from Apis mellifera, sodium benzoate, ethilic alcohol, water) 5ml. Given in single dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with mimicking characteristics of experimental drug
Study: NCT01294917

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-purpose disinfecting solution
Description: For the cleaning, rinsing, and storage of soft contact lenses.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clear Care
Description: Peroxide-based regimen for cleaning and disinfecting soft contact lenses.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Opti-Free RepleniSH
Description: Multi-purpose disinfecting solution for the cleaning, rinsing and storing of soft contact lenses.
Study: NCT03232541

Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Description: A) Standard antiemetic treatment means receiving ordinary antiemetic medications. Within the group, the patients will be randomized to two communication types: 1) neutral communication or 2) strengthened positive communication regarding expected antiemetic effects of their treatment, using a standardized communication model.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham acupuncture
Description: B) Sham acupuncture is administered bilaterally to a non-acupuncture point two body-inches proximal and one body-inch radial from PC6 using the telescopic Park Sham Device. The sham-needle is blunt and glides upward into its handle instead of penetrating. Marking tubes hold the needle in place. The therapist gives an illusion of manipulating the needle by turning it three times until it touches the skin, but no specific needle sensation (deqi) will occur. Within the group, the patients will be randomized to two communication types: 1) neutral communication or 2) strengthened positive communication regarding expected antiemetic effects of their treatment, using a standardized communication model.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Genuine acupuncture
Description: C) Acupuncture will be administered bilaterally to the standard antiemetic point PC6 located two body-inches proximal of the wrist crease, between the tendons of palmaris longus and flexor carpi radialis. Sharp acupuncture needles will be inserted into a depth of a half body-inch. The needles will be manipulated three times (at the start, middle and end of the treatment session) by twirling and lifting until deqi occurres. Within the group, the patients will be randomized to two communication types: 1) neutral communication or 2) strengthened positive communication regarding expected antiemetic effects of their treatment, using a standardized communication model.
Study: NCT01838135

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WheelSeeU Training Program
Description: WheelSeeU sessions will be administered by a peer-trainer (older adult wheelchair user), who will be trained in a 2-day workshop to use social cognitive approaches (i.e. facilitating successful performance of wheelchair skills, learning through observation of peers, positive verbal reinforcement from peers and family members, and re-interpretation of physiological symptoms) to foster the improvement of self-efficacy for wheelchair use. Each WheelSeeU session will be tailored to the individual goals of participants, which will be identified during the start of each session.
Study: NCT03135886

Intervention type: OTHER
Group type: OTHER
Intervention: Information Control
Description: The OTPs assigned to this group will be provided access to the NIDA/SAMHSA Blending Initiative product for HIV rapid testing. Resources generated from the HIV rapid testing Blending Initiative product include a fact sheet, resource guide, marketing materials, and an Excel-based budgeting tool. In addition to the HIV-specific materials, the website provides opportunities for training, self-study progress, workshop, and distance learning. OTPs also will receive a link to the Anti-Retroviral Treatment and Access to Services (ARTAS) intervention training website which provides information and training courses. Sites also will receive a hard (or electronic) copy of the ARTAS implementation manual and information about the provision of HIV testing, linkage to care and PrEP.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIV and HCV Testing Practice Coaching Intervention
Description: The practice coaches (PCs) will work with the program team a) to establish capabilities, reimbursement systems and/or partnerships necessary to support HIV and HCV testing and evidence--based linkage to care and b) to reduce barriers (e.g., staffing, training) to the implementation and sustained provision of HIV and HCV testing. Also, due to the expense of HCV treatment, and potentially more complicated mechanisms for linking HCV-positive patients to further evaluation and care which may take more time than anticipated, PCs will provide OTPs with basic education and motivation about the importance of HCV testing for reasons other than immediate curative treatment. Information on PrEP also will be provided. The intervention will occur over approximately 29 weeks (or 6 months).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIV Testing Practice Coaching Intervention
Description: The practice coaches (PCs) will work with the programs a) to establish capabilities, reimbursement systems and/or partnerships necessary to support HIV testing and evidence-based linkage to care and b) to reduce barriers (e.g., staffing, training) to the implementation and sustained provision of HIV testing. Information on Pre-Exposure Prophylaxis (PrEP) also will be provided. The intervention will occur over approximately 29 weeks (or 6 months) consisting of four distinct evidence-based phases designed to establish competency in the implementation of organizational change towards establishing HIV testing outcomes among OTP clientele.
Study: NCT03906825

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CEAG
Description: Curcuminoids, EPA (OMEGA-3), Astaxanthin, GLA

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT00486486

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: bimatoprost/timolol fixed combination AM
Description: 3-month chronic dosing in the morning

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Drug: bimatoprost/timolol fixed combination AM
Description: 3-month chronic dosing in the morning

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bimatoprost/timolol fixed combination dosed PM
Description: Evening dosing of bimatoprost/timolol fixed combination for a period of 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bimatoprost/timolol fixed combination dosed PM
Description: Evening dosing of bimatoprost/timolol fixed combination for a period of 3 months
Study: NCT02299193

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: 6 weekly, 20 minute online sessions about how thoughts and behaviors can affect sleep

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Healthy Sleep Habits
Description: 6 weekly, 20 minute online sessions about healthy sleep practices
Study: NCT04217343

Intervention type: DIAGNOSTIC_TEST
Intervention: Allosure/Allomap/Cytokines testing
Description: All patients with evidence of Cardiac Transplant rejection will undergo Allosure, Allomap, and cytokine testing. Allosure and Allomap will be performed as part of routine care. Cytokine testing will be performed at time of rejection and resolution.

Intervention type: DIAGNOSTIC_TEST
Intervention: Allosure/Allomap/Cytokines testing
Description: All patients with evidence of Cardiac Transplant rejection will undergo Allosure, Allomap, and cytokine testing. Allosure and Allomap will be performed as part of routine care. Cytokine testing will be performed at time of rejection and resolution.
Study: NCT03757598

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ePartogram use
Description: Electronic partograph based on WHO standard paper partograph is given in Android tablet used by provider monitoring clients in labor. Providers had received training in using the ePartogram and ongoing trouble shooting.
Study: NCT00371267

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-delivered Cognitive Behavior Therapy
Description: Telephone-delivered cognitive behavior therapy for pain management

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telephone-delivered Patient Education
Description: Telephone-delivered patient education regarding chronic pain
Study: NCT03404362

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Metastases Pain treatment
Description: Comparative treatments to test if MRgFUS is an effective non-invasive and safe treatment for the palliation of metastatic bone tumors with a low incidence of co-morbidity as compared to EBRT (gold-standard)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Metastases Pain treatment
Description: Comparative treatments to test if MRgFUS is an effective non-invasive and safe treatment for the palliation of metastatic bone tumors with a low incidence of co-morbidity as compared to EBRT (gold-standard)
Study: NCT01784887

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Procellera
Description: PROCELLERA TM is an FDA-cleared bioelectrical dressing delivered in a sterile, single layer sheet consisting of a flexible polyester fabric layer containing silver and zinc, which are held in position on the polyester with a biocompatible binder.